These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39411068)

  • 21. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
    Wong H; Chow TW
    J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
    Huang HW; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):621-638. PubMed ID: 37947924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
    Iwasaki S; Zhu A; Hanley M; Venkatakrishnan K; Xia C
    AAPS J; 2020 Apr; 22(3):66. PubMed ID: 32291610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
    Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
    MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
    Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
    Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
    Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
    Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):477-492. PubMed ID: 38400996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies.
    Naware S; Bussing D; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):493-508. PubMed ID: 37558929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.
    Zhang L; Mager DE
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):541-52. PubMed ID: 26391023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
    Yan X; Mager DE; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy.
    Koyama S; Toshimoto K; Lee W; Aoki Y; Sugiyama Y
    Drug Metab Dispos; 2021 Apr; 49(4):298-304. PubMed ID: 33558262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.